Calidi Biotherapeutics - התחייבויות לטווח ארוך של החברה CLDI

The historical price action of Calidi Biotherapeutics (CLDI) demonstrates a long-term debt trend, which currently stands at 0.00. The team relies on a dedicated staff of oncologists while actively engaging global certification experts. The business is based on creating targeted drug delivery systems to tumors, leading the way in precision therapy. Stringent GMP manufacturing requirements and patent protection for cell modifications create an insurmountable barrier to entry for new players.

Long-term debt reflects the aggregate of credit obligations with maturities exceeding twelve months. This metric accumulates all long-term loans, demonstrating sensitivity to the cost of borrowed capital. By analyzing the time series of the firm's long-term borrowings, an investor sees the current value of 0.00. Low debt levels confirm the strategy of Calidi Biotherapeutics (CLDI) to minimize capital expenditures. Outsourcing clinical trials allows the company to advance R&D without burdening the balance sheet with costly loans.